Abstract
Abdominal obesity has been linked to the development of insulin resistance and Type 2 diabetes mellitus (DM2). By surgical removal of visceral fat (VF) in a variety of rodent models, we prevented insulin resistance and glucose intolerance, establishing a cause-effect relationship between VF and the metabolic syndrome. To characterize the biological differences between visceral and peripheral fat depots, we obtained perirenal visceral (VF) and subcutaneous (SC) fat from 5 young rats. We extracted mRNA from the fat tissue and performed gene array hybridization using Affymetrix technology with a platform containing 9 000 genes. Out of the 1 660 genes that were expressed in fat tissue, 297 (17.9 %) genes show a two-fold or higher difference in their expression between the two tissues. We present the 20 genes whose expression is higher in VF fat (by 3 - 7 fold) and the 20 genes whose expression is higher in SC fat (by 3 - 150 fold), many of which are predominantly involved in glucose homeostasis, insulin action, and lipid metabolism. We confirmed the findings of gene array expression and quantified the changes in expression in VF of genes involved in insulin resistance (PPARγ leptin) and its syndrome (angiotensinogen and plasminogen activating inhibitor-1, PAI-1) by real-time PCR (qRT-PCR) technology. Finally, we demonstrated increased expression of resistin in VF by around 12-fold and adiponectin by around 4-fold, peptides that were not part of the gene expression platform. These results indicate that visceral fat and subcutaneous fat are biologically distinct.
Key words
Visceral Fat - Subcutaneous Fat - Leptin - Angiotensinogen - Resistin - PPARγ - Adiponectin (ACRP30) - Plasminogen Activating Inhibitor-1 (PAI-1)
References
1
Carey D G, Jenkins A B, Campbell L V, Freund J, Chisholm D J.
Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.
Diabetes.
1996;
45
633-638
2
Coon P J, Rogus E M, Drinkwater D, Muller D C, Goldberg A P.
Role of body fat distribution in the decline in insulin sensitivity and glucose tolerance with age.
J Clin Endocrinol Metab.
1992;
75
1125-1132
3
O’Shaughnessy I M, Myers T J, Stepniakowski K, Nazzaro P, Kelly T M, Hoffmann R G, Egan B M, Kissebah A H.
Glucose metabolism in abdominally obese hypertensive and normotensive subjects.
Hypertension.
1995;
26
186-192
4
Bjorntorp P.
“Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes.
Arteriosclerosis.
1990;
10
493-496
5
Barzilai N, She L, Liu B Q, Vuguin P, Cohen P, Wang J, Rossetti L.
Surgical removal of visceral fat reverses hepatic insulin resistance.
Diabetes.
1999;
48
94-98
6
Gabriely I, Ma X H, Yang X M, Atzmon G, Rajala M W, Berg A H, Scherer P, Rossetti L, Barzilai N.
Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?.
Diabetes.
2002;
51
2951-2958
7
Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L.
Leptin selectively decreases visceral adiposity and enhances insulin action.
J Clin Invest.
1997;
100
3105-3110
8
Barzilai N, Banerjee S, Hawkins M, Chen W, Rossetti L.
Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat.
J Clin Invest.
1998;
101
1353-1361
9
Baker T K, Carfagna M A, Gao H, Dow E R, Li Q, Searfoss G H, Ryan T P.
Temporal gene expression analysis of monolayer cultured rat hepatocytes.
Chem Res Toxicol.
2001;
14
1218-1231
10
Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Loblein K, Maerker E, Volk A, Renn W. et al .
the PPARγ2 polymorphism Pro 12 Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic subjects.
Horm Metab Res.
2000;
32
413-416
11
Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino L J, DeFronzo R A.
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
J Clin Endocrinol Metab.
2002;
87
2784-2791
12
Montague C T, Prins J B, Sanders L, Zhang J, Sewter C P, Digby J, Byrne C D, O’Rahilly S.
Depot-related gene expression in human subcutaneous and omental adipocytes.
Diabetes.
1998;
47
1384-1391
13
Lefebvre A-M, Alville M, Vega N, Riou J P, van Gaal L, Auwerx J, Vidal H.
Depot specific differences in adipose tissue gene expression in lean and obese subjects.
Diabetes.
1998;
47
98-103
14
Hansen T B, Vahl N, Jorgensen J O, Christiansen J S, Hagen C.
Whole body and regional soft tissue changes in growth hormone deficient adults after one year of growth hormone treatment: a double-blind, randomized, placebo-controlled study.
Clin Endocrinol (Oxf).
1995;
43
689-696
15
Brummer R JM, Lonn L, Kvist H, Grangard U, Bengtsson B-A, Sjostrom L.
Adipose tissue and muscle volume determination by computed tomography in acromegaly before and one year after adenomectomy. Eur.
J Clin Invest.
1993;
23
199-205
16
Patsch W, Oberkofler H, Esterbauer H, Breban D, Winkler C, Hell E, Krempler F.
Uncoupling protein-1 mRNA expression: relation to obesity and sequence variations at the UCP-1 gene locus. Eighth international congress on obesity (Paris, France, August 29 - September 3, 1998).
Int J Obes.
1998;
22 (Suppl. 2)
O19-PS6
17
Barzilai N, She L, Liu L, Wang J, Hu M, Vuguin P, Rossetti L.
Decreased visceral adiposity accounts for leptin effect on hepatic but not peripheral insulin action.
Am J Physiol.
1999;
277
E291-E298
18
Gabriely I, Ma X H, Yang X M, Rossetti L, Barzilai N.
Leptin resistance during aging is independent of fat mass.
Diabetes.
2002;
51
1016-1021
19
Ma X H, Muzumdar R, Yang X M, Gabriely I, Berger R, Barzilai N.
Aging is associated with resistance to effects of leptin on fat distribution and insulin action.
J Gerontol A Biol Sci Med Sci.
2002;
57
B225-B231
20
Gabriely I, Yang X M, Cases J A, Ma X H, Rossetti L, Barzilai N.
Hyperglycemia modulates angiotensinogen gene expression.
Am J Physiol Regul Integr Comp Physiol.
2001;
281
R795-R802
21
Giachetti G, Faloia E, Mariniello B, Sardu C, Camilloni M A, Guerrieri M, Montero F.
Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects.
Am J Hypertens.
2002;
15
381-388
22
Alessi M C, Peiretti F, Morange P, Henry M, Nalbone G, Juhanvague I.
Production of plasminogen activator inhibitor-1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease.
Diabetes.
1997;
46
860-867
23
Calles Escandon J, Mirza S A, Sobel B E, Schnieder D J.
Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor-1 in blood of normal human subjects.
Diabetes.
1998;
47
290-293
24
Mertens I, van der Planken M, Corthouts B, Wauters M, Peiffer F, Leeuw I, van Gaal L.
Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
Horm Metab Res.
2001;
33
602-607
25
Gabriely I, Yang X M, Cases J A, Ma X H, Rossetti L, Barzilai N.
Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway.
Atherosclerosis.
2002;
160
115-122
26
Steppan C M, Bailey S T, Bhat S, Brown E J, Banerjee R R, Wright C M, Patel H R, Ahima R S, Lazar M A.
The hormone resistin links obesity to diabetes.
Nature.
2001;
409
307-312
27
Janke J, Engeli S, Gorzelniak K, Lift F C, Sharma A M.
Resistin gene expression in human adipocytes is not related to insulin resistance.
Obes Res.
2002;
10
1-5
28
Scherer P E, Williams S, Fogliano M, Baldini G, Lodish H F.
A novel serum protein similar to C1q, produced exclusively in adipocytes.
J Biol Chem.
1995;
270
26 746-26 749
29
Berg A H, Combs T P, Du X, Brownlee M, Scherer P E.
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.
Nat Med.
2001;
7
947-953
30
Combs T P, Berg A H, Obici S, Scherer P E, Rossetti L.
Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.
J Clin Invest.
2001;
108
1875-1881
N. Barzilai, M.D.
Institute for Aging Research
Belfer Bldg. #701 · Albert Einstein College of Medicine · 1300 Morris Park Avenue · Bronx, NY 10461 · USA ·
Telefon: + 1 (718) 430-33 12
Fax: + 1 (718) 430-85 57
eMail: barzilai@aecom.yu.edu